We report the case of a 40-year-old woman with a medical history of cutaneous erythematous lupus, celiac disease, and anxiety-depressive disorder. Menarche was at age 12 years; her menstruation was regular, although her menstrual flow was irregular. At age 9 years, she was diagnosed with allergic rhinoconjunctivitis and mild persistent asthma with sensitization to pollen and pet dander. Her condition was well controlled with bronchodilators and antihistamines until age 16. She currently works in an office and lives in a house 7 km away from the nearest town, in the Autonomous Community of Madrid, Spain. For the last 7 years, she has kept 3 dogs at home. She has no usual contact with cats or other animals.
At age 16 years, despite receiving maintenance treatment (budesonide/formoterol and montelukast), she started having multiple exacerbations that required rescue medication almost every day and cycles of systemic corticosteroids at various times. One of the crises was triggered every month 3 to 4 days before or simultaneously with menstruation. She had 28-day cycles. Ten years ago, at age 30 years, she had to be admitted to the intensive care unit because of a severe exacerbation secondary to a respiratory infection.
In 2015, the patient was referred to our severe asthma unit. She reported a noticeable improvement in her asthma symptoms when she was using oral contraceptives, a vaginal ring, or a contraceptive implant, all of which she had been using on and off since she was 20 years old. She also reported an improvement during pregnancy that same year. Her asthma exacerbations started again months after the pregnancy. She had symptoms almost every day and at least 1 severe exacerbation a month that required a visit to the emergency department and treatment with systemic corticosteroids. Furthermore, she experienced moderate exacerbations of asthma and rhinoconjunctivitis while in contact with dogs that were not hers and during periods of pollen exposure.
One year ago, she started to experience cough, dyspnea, and wheezing 30 minutes after eating pork. These episodes subsided with bronchodilators. Since then, she has followed a pork-free diet. She tolerates well-done beef and poultry. She also reported that for an unspecified time, she developed rhinoconjunctivitis symptoms and epigastric pain after drinking cow's milk and dairy products. Consequently, she stopped consuming cow's milk but tolerated some dairy products such as cheese.
A diagnostic work-up for severe uncontrolled asthma [1] was followed by high-resolution computed tomography (CT), sinus CT, an immunological study, and a hormonal study. 
87%). Her initial inhalation technique was poor,
and she received appropriate instruction. Serial peak expiratory flow recordings showed a clear drop during perimenstrual periods, during exercise, and at night. Her asthma control test score was 18, and the fractional exhaled nitric oxide value was 42 ppb.
In the allergy work-up, the patient's skin prick test result was positive to pollens (grass and olive tree), molds (Alternaria alternata, Aspergillus fumigatus), dander (cat, dog, hamster, and horse), cow's milk (bovine serum albumin), and pork. The results were negative to veal and chicken. The results for total IgE and specific IgE are shown in the Table, A. The induced sputum differential cell count was 25% neutrophils, 30% eosinophils, and 45% macrophages.
The patient was diagnosed with the following conditions: (1) severe uncontrolled allergic asthma (with marked sensitization to animal dander) worsened by menstruation; (2) rhinoconjunctivitis due to sensitization to pollens and animal dander; and (3) bronchospasm after ingestion of pork and rhinoconjunctivitis after ingestion of cow's milk (due to sensitization to bovine serum albumin). In 2016, treatment was started with omalizumab, tiotropium bromide, beclomethasone/formoterol, desloratadine, nasal fluticasone, montelukast, a pork and cow's milk-free diet, and a hormonal implant (Implanon, etonogestrel). Good control of asthma was achieved.
In 2017, the symptoms reappeared with menstruation and remained stable between menstrual periods. Spirometry was performed during 3 menstrual exacerbations and at baseline, with a noticeable decrease in FEV 1 and no modification in peripheral eosinophilia or FeNO levels (Table, B) .
A new implant was placed because of the suspicion of loss of efficacy of the hormonal implant (even though its estimated efficacy period was 3 years). Subsequently, the patient's condition was controlled and has remained good with better pulmonary function to date.
The incidence of asthma is higher in postpubertal females than in postpubertal males [2] . This difference can probably be attributed to female sex steroids [2] . In patients aged <12 years, menarche and early menarche have been associated with an increased risk of asthma [2] , which can also lead to the participation of hormones in the development of asthma. Perimenstrual asthma (PMA) is usually described as a cyclical deterioration of asthma during the luteal phase and/or during the first days of menstruation [3] . Women with PMA require more bursts of corticosteroid therapy and have a higher risk of visits to the emergency department, hospitalization, admission to the intensive care unit [3] , intubation, and near fatal and fatal events [4] .
Asthma exacerbations in the perimenstrual period are not associated with peripheral blood eosinophilia [5] . In the case report, we were unable to demonstrate peripheral blood eosinophilia in any of the perimenstrual exacerbations.
Mammal serum albumins behave as panallergens [6] , thus explaining the sensitization of the present patient to cow, dog, horse, and pork albumin. Sensitization to ≥2 dog and cat allergens and sensitization to albumins are associated with more severe respiratory symptoms [6] , as we report here. It is very unusual to be sensitized to albumin and have PMA. The only previous case described to date involved sensitization to cow's milk albumin associated with exacerbations during the premenstrual period with exercise as a cofactor [7] .
Oral contraception is one of the most common treatments for PMA, even though the specific contraceptive and the ideal dosage have not been established. Their benefit is the regulation of hormonal changes during the cycle, as suggested elsewhere [8] .
The use of biologic therapies, such as anti-IgE monoclonal antibodies (omalizumab), has not been previously reported in patients with PMA and severe allergic asthma. In the present case, omalizumab did not control the exacerbations owing to menstruation. However, it successfully controlled daily asthma symptoms and allergen-related exacerbations [9] . Even though the first line of treatment in patients with animal allergies is to remove the pet from the home and avoid contact [6] , the patient refused to follow this recommendation, thus explaining why we had to look for alternative treatments.
The multiple factors involved (immunologic, psychological, uncommon allergic triggers, and menstruation) make the management of this patient quite complex. The case illustrates that periodic monitoring remains essential to regain asthma control [10] . Similarly, in a case of PMA in a patients with a hormonal implant (such as that reported here), loss of efficacy should be suspected. To the best of our knowledge, this is the first reported case with these clinical features.
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The authors declare that no funding was received for the present study. Human glucagon-like peptide 1 (GLP-1) is an incretin hormone that was initially described in the 1980s as a proglucagon cleavage product, produced by intestinal cells in response to food intake [1] . Its main actions are stimulation of insulin secretion, suppression of glucagon production, delay in gastric emptying, induction of satiety in the central nervous system, and reduction of postprandial triglyceride and free fatty acid concentrations [2] . Given its main hypoglycemic properties, GLP-1 has become an important therapeutic target in type 2 diabetes. However, a major limitation of its use was its very short half-life [2] . This was overcome by the development of synthetic GLP-1 receptor agonists, which can be divided into short-acting GLP-1 receptor agonists (exenatide and lixisenatide) and long-acting GLP-1 receptor agonists (longacting release [LAR] exenatide, liraglutide, albiglutide, and dulaglutide).
Exenatide, which has been approved in Europe since 2006, is a short-acting GLP-1 receptor agonist with a halflife of 2.4 hours that is administered subcutaneously twice daily. Its main action is lowering postprandial glucose levels by delaying gastric emptying. LAR exenatide was approved in Europe in 2011 and enables a constant drug plasma level with once-weekly subcutaneous administration. This is possible due to its composition (microspheres of biodegradable polymeric matrix containing exenatide), which enables slow release of exenatide as a result of breakdown of the microspheres. LAR exenatide has a more marked insulinotropic effect than exenatide, with more pronounced lowering of fasting glucose plasma levels, thus providing better glycemic control. Another advantage is its convenient weekly administration.
We report the case of a 66-year-old woman with a 10-year personal history of type 2 diabetes and no target organ lesions who was treated with oral antidiabetic drugs
